Circulating scd14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in hiv/hcv co-infected patients

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Marchetti, Giulia ^a   Nasta, Paola ^b   Bai, Francesca ^a   Gatti, Francesca ^b   Bellistrì, Giusi Maria ^a   Tincati, Camilla ^a   Borghi, Federica ^b   Carosi, Giampiero ^b   Puoti, Massimo ^c   d'Arminio Monforte, Antonella ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LIPOPOLYSACCHARIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ALPHA INTERFERON; BIOLOGICAL MARKER; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; EARLY VIROLOGICAL RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MICROBIAL TRANSLOCATION; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; MIXED INFECTION; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SCORING SYSTEM; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; VIRUS LOAD; BACTERIUM; BLOOD; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DEMOGRAPHY; DRUG EFFECT; FIBROSIS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MICROBIOLOGY; MIDDLE AGED; SOLUBILITY; TREATMENT OUTCOME; VIROLOGY;

ADULT; ANTIGENS, CD14; BACTERIA; BIOLOGICAL MARKERS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COINFECTION; DEMOGRAPHY; FEMALE; FIBROSIS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HLA-DR ANTIGENS; HUMANS; INTERFERON-ALPHA; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SOLUBILITY; TREATMENT OUTCOME;

EID: 84857386483     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032028     Document Type: Article

References (51)

1. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, et al. (2005) Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 192: 992-1002.
2. Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, et al. (2008) Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 198: 1337-1344.
3. Bica I, McGovern B, Dhar R, Stone D, McGowan K, et al. (2001) Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32: 492-497.
4. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, et al. (2001) Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 33: 562-569.
5. Rosenthal E, Salmon-Céron D, Lewden C, Bouteloup V, Pialoux G, et al. (2009) Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19). HIV Med 10: 282-289.
6. Puoti M, Prestini K, Putzolu V, Zanini B, Baiguera C, et al. (2003) HIV/HCV co-infection: natural history. J Biol Regul Homeost Agents 17: 144-146.
7. Bruno R, Sacchi P, Puoti M, Soriano V, Filice G, (2002) HCV chronic hepatitis in patients with HIV: clinical management issues. Am J Gastroenterol 97: 1598-1606.
8. Bruno R, Sacchi P, Puoti M, Maiocchi L, Patruno S, et al. (2007) Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. J Acquir Immune Defic Syndr 46: 297-303.
9. Blackard JT, Sherman KE, (2008) HCV/HIV co-infection: time to re-evaluate the role of HIV in the liver? J Viral Hepat 15: 323-330.
10. Rockstroh JK, (2006) Influence of viral hepatitis on HIV infection. J Hepatol 44: S25-27.
11. Berzsenyi MD, Bowden DS, Kelly HA, Watson KM, Mijch AM, et al. (2007) Reduction in hepatitis C-related liver disease associated with GB virus C in human immunodeficiency virus coinfection. Gastroenterology 133: 1821-1830.
12. McGovern BH, (2007) Hepatitis C in the HIV-infected patient. J Acquir Immune Defic Syndr 45 (Suppl 2): S47-56 discussion S66-47.
13. Gonzalez VD, Falconer K, Blom KG, Reichard O, Mørn B, et al. (2009) High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol 83: 11407-11411.
14. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
15. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, et al. (2010) Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138: 1338-1345, 1345.e1331-1337.
16. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.
17. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109.
18. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, et al. (2011) Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140: 1021-1031.
19. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC, (2007) Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 22: 832-836.
20. Elefsiniotis IS, Vezali E, Mihas C, Saroglou G, (2009) Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Intervirology 52: 247-251.
21. Wyles DL, (2010) Moving beyond interferon alfa: investigational drugs for hepatitis C virus infection. Top HIV Med 18: 132-136.
22. Vermehren J, Sarrazin C, (2011) New HCV therapies on the horizon. Clin Microbiol Infect 17: 122-134.
23. Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, et al. (2005) Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434: 1093-1097.
24. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, et al. (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12: 1365-1371.
25. Marchetti G, Cozzi-Lepri A, Merlini E, Bellistrì GM, Castagna A, et al. (2011) Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS 25: 1385-1394.
26. Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, et al. (2009) Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis 199: 1177-1185.
27. Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, et al. (2011) Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 141: 1220-1230, 1230.e1221-1223.
28. Dolganiuc A, Norkina O, Kodys K, Catalano D, Bakis G, et al. (2007) Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection. Gastroenterology 133: 1627-1636.
29. Gaeta GB, Perna P, Adinolfi LE, Utili R, Ruggiero G, (1982) Endotoxemia in a series of 104 patients with chronic liver diseases: prevalence and significance. Digestion 23: 239-244.
30. Bode C, Kugler V, Bode JC, (1987) Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J Hepatol 4: 8-14.
31. Harte AL, da Silva NF, Creely SJ, McGee KC, Billyard T, et al. (2010) Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond) 7: 15.
32. Caradonna L, Mastronardi ML, Magrone T, Cozzolongo R, Cuppone R, et al. (2002) Biological and clinical significance of endotoxemia in the course of hepatitis C virus infection. Curr Pharm Des 8: 995-1005.
33. Balagopal A, Philp FH, Astemborski J, Block TM, Mehta A, et al. (2008) Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 135: 226-233.
34. Castera L, Forns X, Alberti A, (2008) Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48: 835-847.
35. Thurman RG, (1998) II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am J Physiol 275: G605-611.
36. Enomoto N, Yamashina S, Kono H, Schemmer P, Rivera CA, et al. (1999) Development of a new, simple rat model of early alcohol-induced liver injury based on sensitization of Kupffer cells. Hepatology 29: 1680-1689.
37. Farnik H, Mihm U, Zeuzem S, (2009) Optimal therapy in genotype 1 patients. Liver Int 29 (Suppl 1): 23-30.
38. Kamal SM, (2009) Hepatitis C genotype 4 therapy: increasing options and improving outcomes. Liver Int 29 (Suppl 1): 39-48.
39. Kovacs A, Karim R, Mack WJ, Xu J, Chen Z, et al. (2010) Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis 201: 823-834.
40. Gonzalez VD, Landay AL, Sandberg JK, (2010) Innate immunity and chronic immune activation in HCV/HIV-1 co-infection. Clin Immunol 135: 12-25.
41. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, et al. (2003) T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 187: 1534-1543.
42. Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, et al. (2008) Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS One 3: e1915.
43. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, et al. (2004) Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104: 942-947.
44. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801.
45. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 105: 7034-7039.
46. Chen L, Borozan I, Feld J, Sun J, Tannis LL, et al. (2005) Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128: 1437-1444.
47. Asselah T, Bieche I, Narguet S, Sabbagh A, Laurendeau I, et al. (2008) Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 57: 516-524.
48. Sarasin-Filipowicz M, Wang X, Yan M, Duong FH, Poli V, et al. (2009) Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol 29: 4841-4851.
49. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, et al. (2010) IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52: 1888-1896.
50. Brettschneider J, Ecker D, Bitsch A, Bahner D, Bogumil T, et al. (2002) The macrophage activity marker sCD14 is increased in patients with multiple sclerosis and upregulated by interferon beta-1b. J Neuroimmunol 133: 193-197.
51. Rempel H, Sun B, Calosing C, Pillai SK, Pulliam L, (2010) Interferon-alpha drives monocyte gene expression in chronic unsuppressed HIV-1 infection. AIDS 24: 1415-1423.